Zobrazeno 1 - 10
of 231
pro vyhledávání: '"Eleanor N Fish"'
Autor:
Mandy Kader Konde, Darren P Baker, Fode Amara Traore, Mamadou Saliou Sow, Alioune Camara, Alpha Amadou Barry, Doussou Mara, Abdoulaye Barry, Moussa Cone, Ibrahima Kaba, Amento Ablam Richard, Abdoul Habib Beavogui, Stephan Günther, European Mobile Laboratory Consortium, Melania Pintilie, Eleanor N Fish
Publikováno v:
PLoS ONE, Vol 12, Iss 2, p e0169255 (2017)
To date there are no approved antiviral drugs for the treatment of Ebola virus disease (EVD). Based on our in vitro evidence of antiviral activity of interferon (IFN)-ß activity against Ebola virus, we conducted a single arm clinical study in Guinea
Externí odkaz:
https://doaj.org/article/6943a7be0f2747f8b090293706f9efd7
Autor:
Stephen D S McCarthy, Beata Majchrzak-Kita, Trina Racine, Hannah N Kozlowski, Darren P Baker, Thomas Hoenen, Gary P Kobinger, Eleanor N Fish, Donald R Branch
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 10, Iss 1, p e0004364 (2016)
To date there are no approved antiviral drugs for the treatment of Ebola virus disease (EVD). While a number of candidate drugs have shown limited efficacy in vitro and/or in non-human primate studies, differences in experimental methodologies make i
Externí odkaz:
https://doaj.org/article/43d4ca5d81fb4934baa7a39b30fd70ad
Autor:
Danlin Jia, Ramtin Rahbar, Renee W Y Chan, Suki M Y Lee, Michael C W Chan, Ben Xuhao Wang, Darren P Baker, Bing Sun, J S Malik Peiris, John M Nicholls, Eleanor N Fish
Publikováno v:
PLoS ONE, Vol 5, Iss 11, p e13927 (2010)
Type I interferons (IFNs) function as the first line of defense against viral infections by modulating cell growth, establishing an antiviral state and influencing the activation of various immune cells. Viruses such as influenza have developed mecha
Externí odkaz:
https://doaj.org/article/8c0f5d8c214f42d38650d89baf78a12d
Autor:
Carole L Galligan, Janet C Siebert, Katherine A Siminovitch, Edward C Keystone, Vivian Bykerk, Omar D Perez, Eleanor N Fish
Publikováno v:
PLoS ONE, Vol 4, Iss 8, p e6703 (2009)
BACKGROUND:The precise mechanisms involved in the initiation and progression of rheumatoid arthritis (RA) are not known. Early stages of RA often have non-specific symptoms, delaying diagnosis and therapy. Additionally, there are currently no establi
Externí odkaz:
https://doaj.org/article/81995df7cd15419cb4d328cda0935399
Autor:
José A. Castro-Rodriguez, Eleanor N. Fish, Samuel T. Montgomery, Tobias R. Kollmann, Carolina Iturriaga, Casey Shannon, Yuliya Karpievitch, Joseph Ho, Virginia Chen, Robert Balshaw, Rym Ben-Othman, Radhouane Aniba, Francisca Gidi-Yunge, Lucy Hartnell, David G. Hancock, Guillermo Pérez-Mateluna, Marcela Urzúa, Scott J. Tebbutt, Diego García-Huidobro, Cecilia Perret, Arturo Borzutzky, Stephen M. Stick
Publikováno v:
EClinicalMedicine, Vol 62, Iss , Pp 102082- (2023)
Summary: Background: Accumulating evidence indicates that an early, robust type 1 interferon (IFN) response to SARS-CoV-2 is important in determining COVID-19 outcomes, with an inadequate IFN response associated with disease severity. Our objective w
Externí odkaz:
https://doaj.org/article/d8d8e7c67f0844a18d712d629bff8ce5
Autor:
Diana Saleiro, Jeremy Q. Wen, Ewa M. Kosciuczuk, Frank Eckerdt, Elspeth M. Beauchamp, Chidera V. Oku, Gavin T. Blyth, Mariafausta Fischietti, Liliana Ilut, Marco Colamonici, William Palivos, Paula A. Atsaves, Dean Tan, Masha Kocherginsky, Rona Singer Weinberg, Eleanor N. Fish, John D. Crispino, Ronald Hoffman, Leonidas C. Platanias
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-19 (2022)
Interferon alpha (IFNalpha) therapy is showing promising results to treat myeloproliferative neoplasms (MPNs). Here, the authors show that IFNalpha response requires ULK1 phosphorylation to induce p38-MAPK signalling but it is counteracted by ROCK1-2
Externí odkaz:
https://doaj.org/article/3a0f1e5129e84efda5acd4754ca85e1b
Autor:
Carolina Iturriaga, Nat Eiffler, Rad Aniba, Rym Ben-Othman, Guillermo Perez-Mateluna, Jessica K. V. Meyer, Eleanor N. Fish, Tobias R. Kollmann, Nicolas Severino, Stephen Stick, Arturo Borzutzky, Cecilia Perret, José A. Castro-Rodriguez, Diego Garcia-Huidobro
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Background SARS-CoV-2 infection rapidly spreads in populations due to the high rates of community transmission. Interrupting the shedding of SARS-CoV-2 may reduce the incidence of Coronavirus Disease 19 (COVID-19). Herein we provide a protoc
Externí odkaz:
https://doaj.org/article/60f714c94caf4155b56bf4aac058f1d8
Autor:
Arthur Viodé, Kinga K. Smolen, Benoit Fatou, Zainab Wurie, Patrick Van Zalm, Mandy Kader Konde, Balla Moussa Keita, Richard Amento Ablam, Eleanor N. Fish, Hanno Steen
Publikováno v:
mBio, Vol 13, Iss 3 (2022)
ABSTRACT Ebola virus (EBV) disease (EVD) is a highly virulent systemic disease characterized by an aggressive systemic inflammatory response and impaired vascular and coagulation systems, often leading to uncontrolled hemorrhaging and death. In this
Externí odkaz:
https://doaj.org/article/624f8327b3f4481fbb8b444be734402a
Autor:
Diana Saleiro, Ewa M. Kosciuczuk, Mariafausta Fischietti, Ricardo E. Perez, G. Sohae Yang, Frank Eckerdt, Elspeth M. Beauchamp, Ye Hou, Qixuan Wang, Rona Singer Weinberg, Eleanor N. Fish, Feng Yue, Ronald Hoffman, Leonidas C. Platanias
Publikováno v:
Cancer Research Communications. 3:943-951
Interferons (IFNs) are cytokines with potent antineoplastic and antiviral properties. IFNα has significant clinical activity in the treatment of myeloproliferative neoplasms (MPN), but the precise mechanisms by which it acts are not well understood.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc08a67b4a95eb295e0a55a7cae3a24c
https://doi.org/10.1158/2767-9764.crc-23-0010
https://doi.org/10.1158/2767-9764.crc-23-0010
Autor:
Christine Stabell Benn, Nelly Amenyogbe, Anders Björkman, Jorge Domínguez-Andrés, Eleanor N. Fish, Katie L. Flanagan, Sabra L. Klein, Tobias R. Kollmann, Kirsten Ohm Kyvik, Mihai G. Netea, Naja Hulvej Rod, Frederik Schaltz-Buchholzer, Frank Shann, Liisa Selin, Sanne M. Thysen, Peter Aaby
Publikováno v:
Drug Safety, 46, 439-448
Benn, C S, Amenyogbe, N, Bjorkman, A, Dominguez-Andres, J, Fish, E N, Flanagan, K L, Klein, S L, Kollmann, T R, Kyvik, K O, Netea, M G, Rod, N H, Schaltz-Buchholzer, F, Shann, F, Selin, L, Thysen, S M & Aaby, P 2023, ' Implications of Non-Specific Effects for Testing, Approving, and Regulating Vaccines ', Drug Safety, vol. 46, pp. 439-448 . https://doi.org/10.1007/s40264-023-01295-3
Drug Safety, 46, 5, pp. 439-448
Benn, C S, Amenyogbe, N, Bjorkman, A, Dominguez-Andres, J, Fish, E N, Flanagan, K L, Klein, S L, Kollmann, T R, Kyvik, K O, Netea, M G, Rod, N H, Schaltz-Buchholzer, F, Shann, F, Selin, L, Thysen, S M & Aaby, P 2023, ' Implications of Non-Specific Effects for Testing, Approving, and Regulating Vaccines ', Drug Safety, vol. 46, pp. 439-448 . https://doi.org/10.1007/s40264-023-01295-3
Drug Safety, 46, 5, pp. 439-448
The current framework for testing and regulating vaccines was established before the realization that vaccines, in addition to their effect against the vaccine-specific disease, may also have “non-specific effects” affecting the risk of unrelated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25515580bee3ed6a7a9fcb03af374d7e
https://hdl.handle.net/2066/292761
https://hdl.handle.net/2066/292761